This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Exubera Getting More Review

Pfizer (PFE - Get Report) said Friday that the Food and Drug Administration will need an extra three months to review its application for the inhaled insulin Exubera.

No explanation was given by Pfizer or its marketing partner Sanofi-Aventis (SNY - Get Report).

The agency needs more time to review "additional technical chemistry data" from the companies. Pfizer and Sanofi-Aventis said they will "continue to work closely with the FDA so that this important medicine can be made available for patients."

Exubera is one of several inhaled insulin products in development, and it's far ahead of competitors in the regulatory review process. The FDA had been expected to act today.

Shares of both companies weren't affected. Pfizer's stock was up 16 cents to $21.26, while Sanofi-Aventis' stock was up 1 cent to $39.54.

However, shares of Nektar Therapeutics (NKTR - Get Report), the company that developed the inhalation technology, dropped 45 cents, or 3.1%, to $14.31 in heavy trading. The stock dipped as low as $13.63.

"This appears to be a minor delay, with approval likely delayed to the end of January 2006," according to a research note from Sagient Research Systems of San Diego, whose BioMedTracker report analyzes biotechnology issues. "We continue to believe that the FDA will accept the advisory committee recommendations to approve Exubera for patients without underlying lung abnormalities."

Last month, an FDA advisory committee recommended approval of Exubera for treating adults with type 1 and type 2 diabetes. Type 1 diabetes is caused by the body's inability to produce insulin, the protein hormone that helps turn sugar into fuel for the body's cells. Type 2 diabetes, which is much more common, is caused by cells ignoring insulin or the body's failure to produce enough insulin.

The advisory panel vote was 7-2. Although the FDA isn't bound by panels' recommendations, it usually follows their advice.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NKTR $11.94 0.00%
PFE $29.03 0.00%
SNY $39.82 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs